Tue, November 29, 2022

Akash Tewari Maintained (BMRN) at Strong Buy with Increased Target to $120 on, Nov 29th, 2022

Akash Tewari of Jefferies, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Increased Target from $100 to $120 on, Nov 29th, 2022.

Akash has made no other calls on BMRN in the last 4 months.



There are 8 other peers that have a rating on BMRN. Out of the 8 peers that are also analyzing BMRN, 1 agrees with Akash's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Maintained at Hold with Increased Target to $95 on, Thursday, October 13th, 2022


These are the ratings of the 7 analyists that currently disagree with Akash


  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Increased Target to $110 on, Monday, October 31st, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $113 on, Thursday, October 27th, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $110 on, Thursday, October 27th, 2022
  • Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $112 on, Monday, October 24th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $128 on, Tuesday, August 9th, 2022
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $125 on, Thursday, August 4th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $122 on, Thursday, August 4th, 2022